A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Washington University School of Medicine
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Barbara Ann Karmanos Cancer Institute
Alliance for Clinical Trials in Oncology
University of Nebraska
OHSU Knight Cancer Institute
Herlev Hospital
Sun Yat-sen University
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Royal Marsden NHS Foundation Trust
University of Arizona
Gruppo Italiano Malattie EMatologiche dell'Adulto
Case Comprehensive Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Asan Medical Center
Stanford University
Royal Marsden NHS Foundation Trust
Stanford University
St. Jude Children's Research Hospital
Masonic Cancer Center, University of Minnesota
University of Louisville
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Francisco
OHSU Knight Cancer Institute
Newcastle-upon-Tyne Hospitals NHS Trust
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Istituto Clinico Humanitas
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center